Roxbury Financial LLC Grows Stock Holdings in Natera, Inc. $NTRA

Roxbury Financial LLC raised its holdings in Natera, Inc. (NASDAQ:NTRA) by 458.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 5,024 shares of the medical research company’s stock after acquiring an additional 4,124 shares during the period. Natera accounts for about 1.1% of Roxbury Financial LLC’s holdings, making the stock its 23rd biggest position. Roxbury Financial LLC’s holdings in Natera were worth $1,364,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC grew its position in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC lifted its position in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the period. Focus Partners Wealth boosted its stake in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after buying an additional 474 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in Natera in the 2nd quarter worth about $298,000. Finally, WINTON GROUP Ltd purchased a new stake in Natera in the 2nd quarter valued at about $558,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 1,204 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total transaction of $305,900.28. Following the completion of the sale, the insider owned 132,429 shares in the company, valued at approximately $33,646,236.03. The trade was a 0.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 1,863 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.38, for a total transaction of $464,594.94. Following the sale, the chief financial officer directly owned 52,432 shares of the company’s stock, valued at approximately $13,075,492.16. This trade represents a 3.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 173,469 shares of company stock worth $39,310,838 over the last 90 days. Company insiders own 5.05% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $267.76 on Monday. The business has a 50-day moving average of $246.77 and a two-hundred day moving average of $222.13. The firm has a market capitalization of $38.35 billion, a PE ratio of -164.27 and a beta of 1.51. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NTRA. Sanford C. Bernstein initiated coverage on shares of Natera in a research note on Friday, June 26th. They set an “outperform” rating and a $310.00 price objective for the company. BTIG Research set a $275.00 target price on shares of Natera and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Royal Bank Of Canada assumed coverage on shares of Natera in a report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 target price for the company. Barclays dropped their price target on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. increased their price target on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.